Medication info
CoAprovel 300/12.5 mg Tablets

CoAprovel 300/12.5 mg Tablets

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›300mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Handok Co., Ltd.
Appearance
Pink, biconvex, oval film-coated tablet with a heart shape engraved on one side and the number '2876' engraved on the other side.
Packaging
3X10 tablets/blister, 100 tablets/bottle
Approval status
Active

MFDS item code 200702136 · Notified 2007.02.16 · Insurance code 652101270

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Administer this medicine once daily, regardless of meals. Titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. This medicine may be administered in combination with other antihypertensive agents if needed. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized by taking into consideration baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with a single agent. The usual starting regimen is 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid has been depleted, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.
Child dose
○ Children Children and adolescents under 18 years: The safety and efficacy of this medicine have not been established.

Ingredients

Manufacturer
Handok Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used to treat essential hypertension and helps patients reach target blood pressure through combination therapy when single therapy is insufficient or in cases of moderate to severe hypertension. It effectively lowers blood pressure, reduces the risk of cardiovascular diseases, and maintains a healthy life. This treatment is particularly suitable for patients who need to combine multiple medications due to high blood pressure. Therefore, this medication is used to improve blood pressure in patients with essential hypertension.

How to take

Adult dose

Administer this medicine once daily, regardless of meals. Titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. This medicine may be administered in combination with other antihypertensive agents if needed. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized by taking into consideration baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with a single agent. The usual starting regimen is 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid has been depleted, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.

Child dose

○ Children Children and adolescents under 18 years: The safety and efficacy of this medicine have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women, so it must be discontinued immediately upon confirmation of pregnancy. It should not be taken by women who are pregnant or breastfeeding, patients allergic to specific medications, or patients with severely impaired kidney function. Additionally, caution must be taken in patients with low blood pressure, kidney disease, liver disease, heart disease, and those with a history of skin cancer or psoriasis. There may be side effects such as dizziness, fatigue, nausea, and urinary abnormalities during the course of this medication, so it is important to regularly monitor kidney function and electrolyte levels through blood tests. Caution should be exercised as dizziness may occur during activities like driving or operating machinery, and if symptoms of low blood pressure arise, medical consultation should be sought immediately. This medication can be used in combination with other antihypertensive medications; however, interactions can occur with lithium and certain potassium-related medications, so consultation with a specialist is advised when taken together. Diabetic patients should monitor blood sugar levels periodically and adjust doses as necessary since this medication may affect glucose control. Moreover, it may increase sensitivity to sunlight, so adequate UV protection is necessary during treatment, and any skin abnormalities should be reported to a healthcare professional immediately. In case of overdose, symptoms such as low blood pressure, dehydration, and electrolyte imbalances may occur; therefore, adherence to prescribed dosages is crucial. Lastly, it is not recommended for children and adolescents as safety and effectiveness have not been established.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • elevated creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 87 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • taste disturbance
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • renal impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • weakness
  • dyspepsia
  • nausea
  • headache
  • tinnitus
  • myalgia
  • increased plasma creatine kinase
  • arthralgia
  • tachycardia
  • hepatitis
  • abnormal liver function
  • kidney failure
  • depression
  • sleep disorders
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • respiratory distress
  • acute respiratory distress syndrome
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • appetite loss
  • interstitial nephritis
  • renal dysfunction
  • jaundice
  • transient blurred vision
  • xanthopsia
  • acute angle-closure glaucoma
  • acute myopia
  • choroidal exudate
  • weakness
  • muscle cramps
  • anaphylactoid reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • erythema nodosum-like reaction
  • erythema nodosum reactivation
  • photosensitivity reaction
  • rash
  • urticaria
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol
  • elevated triglycerides
  • lip cancer
  • hypoglycemia
  • intestinal vascular edema
  • herpes zoster
  • colon cancer
  • hematoma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius to preserve the drug's efficacy and safety.

Appearance and packaging

Appearance

Pink, biconvex, oval film-coated tablet with a heart shape engraved on one side and the number '2876' engraved on the other side.

Package unit

3X10 tablets/blister, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.